TTR and cardiac amyloidosis: ATTR-ACT is a phase III multicenter double-blinded study assessing 441 patients of cardiac amyloidosis, 106 with ATTRm (familial transthyretin-associated forms of amyloid) and 335 with ATTRwt (wild-type transthyretin-associated forms of amyloid) [12].